Literature DB >> 1374294

Chemical modification of fumagillin. I. 6-O-acyl, 6-O-sulfonyl, 6-O-alkyl, and 6-O-(N-substituted-carbamoyl)fumagillols.

S Marui1, F Itoh, Y Kozai, K Sudo, S Kishimoto.   

Abstract

The hydroxy group of fumagillol (3), a degradation product of fumagillin (1), was acylated, sulfonylated, alkylated or carbamoylated, and the anti-angiogenic activity of the resulting products was examined. These compounds inhibited the angiogenesis induced by basic fibroblast growth factor in the rat corneal micropocket assay and the growth of vascular endothelial cells in vitro. Among them, compound 2 (AGM-1470) was found to show the most potent inhibitory effect on the growth of vascular endothelial cells and was selected from this series as a candidate for further development.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374294     DOI: 10.1248/cpb.40.96

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  8 in total

1.  The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest.

Authors:  J R Yeh; R Mohan; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

2.  Orally active fumagillin analogues: transformations of a reactive warhead in the gastric environment.

Authors:  Christopher C Arico-Muendel; Heather Blanchette; Dennis R Benjamin; Teresa M Caiazzo; Paolo A Centrella; Jennifer DeLorey; Elisabeth G Doyle; Steven R Johnson; Matthew T Labenski; Barry A Morgan; Gary O'Donovan; Amy A Sarjeant; Steven Skinner; Charles D Thompson; Sarah T Griffin; William Westlin; Kerry F White
Journal:  ACS Med Chem Lett       Date:  2013-02-22       Impact factor: 4.345

3.  Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.

Authors:  S Yanai; H Okada; K Saito; Y Kuge; M Misaki; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

4.  Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.

Authors:  T Yazaki; Y Takamiya; P C Costello; T Mineta; A G Menon; S D Rabkin; R L Martuza
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

5.  Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; Y Saitoh; S Izumoto; K Mori; T Hayakawa
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Common therapeutic target for both cancer and obesity.

Authors:  Yie-Hwa Chang
Journal:  World J Biol Chem       Date:  2017-05-26

7.  Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.

Authors:  J Mu; Y Abe; T Tsutsui; N Yamamoto; X G Tai; O Niwa; T Tsujimura; B Sato; H Terano; H Fujiwara; T Hamaoka
Journal:  Jpn J Cancer Res       Date:  1996-09

8.  Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).

Authors:  M Kusaka; K Sudo; E Matsutani; Y Kozai; S Marui; T Fujita; D Ingber; J Folkman
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.